Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04536740
Other study ID # SH9H-2020-T290-1
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 1, 2020
Est. completion date September 30, 2022

Study information

Verified date August 2020
Source Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Contact Gang Ma
Phone 021-23271699
Email docmagang@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Port-wine stain (PWS) is a congenital capillary malformation with an incidence of 3-5/1000 newborns and grows commensurately with the affected individual.

Although PDL treatment can significantly lighten and reduce most PWS lesions, 20% of cases show little improvement after treatment. Our previous researches suggested that PDT may be a beneficial option for PWS cases that are resistant to multiple PDL treatments.

In this study, a single center, prospective, parallelled, controlled study was conducted to compare the efficacy of PDT on PWS treated with standard PDL and those without any treatment.


Description:

Port-wine stain (PWS) is a congenital capillary malformation characterized by ectatic capillaries and postcapillary venules located predominantly in the papillary and mid-reticular layers of the dermis. It has an incidence of 3-5/1000 newborns and grows commensurately with the affected individual.

Pulsed dye laser (PDL) of 585 and 595 nm is considered to be the gold standard for treating PWS. Although PDL treatment can significantly lighten and reduce most PWS lesions, 20% of cases show little improvement after treatment. This ratio therefore represents a relatively large number of patients who may benefit from an alternative treatment modality.

Vascular-targeted photodynamic therapy (PDT) has been used to treat PWS since the 1990s. In 1990, Orenstein et al. used a chicken comb model to show that PDT can treat hypervascular dermal lesions while leaving the normal overlying epidermis completely intact. The use of vascular-targeted PDT for treating PWS was first described in 1991. PDT can theoretically target ectatic capillaries of all diameters and, in contrast to PDL, can induce vascular damage deeper in the dermis, with a considerably reduced risk of epidermal necrosis due to its vascular-selective characteristics. Previous studies have also demonstrated that PDT is an effective and safe means of improving the appearance of PWS.

Our previous researches suggested that PDT may be a beneficial option for PWS cases that are resistant to multiple PDL treatments.Therefore, the choice of early treatment for PWS is very important . The effect of PDL therapy on the follow-up photodynamic treatment of PWS unknown.

In this study, a single center, prospective, parallelled, controlled study was conducted to compare the efficacy of PDT on PWS treated with standard PDL and those without any treatment. Our objectis to explore whether the previous PDL treatment will affect the efficacy of the follow-up PDT on PWS, so as to provide early treatment options for children with PWS.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 68
Est. completion date September 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Year to 14 Years
Eligibility Inclusion Criteria:

- Patients aged 1-14 years who met the criteria for diagnosis of port-wine stain in The International Society for the Study of Vascular Anomalies(ISSVA);

- Patients in the untreated group had never received any treatment;

- Patients in the PDL-treated group received at least five 595 nm pulse dye laser (PDL) treatment (Vbeam laser; candela Corp., Boston, MA), The time interval between

- Photodynamic therapy and the last pulse dye laser treatment was at least 3 months;

- There were complete medical records, standard photos and test records before and after treatment;

- After fully understanding the treatment plan and risks, patients voluntarily signed the informed consent and was willing to accept clinical trials and cooperate with follow-up.

Exclusion Criteria:

- Original infection, eczema, ulcers in the lesion site; The patient has a history of seizures in the last six months or the condition is not under control;

- Hypersensitivity to porphyrins, hypersensitivity constitution;

- Scar constitution;

- A history of heavily UV exposure in the last 3 months;

- With abnormal electrocardiogram, heart disease, liver damage, pregnancy or other underlying diseases that may affect treatment;

- Patients are participating in other clinical trials.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PDT treatment device
All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gang Ma

Outcome

Type Measure Description Time frame Safety issue
Primary Visual evaluation Standard digital photographs were obtained using consistent camera settings (EOS 80D; Canon, Tokyo, Japan), light conditions and patient positions. Three independent, blinded assessors qualitatively assessed color blanching Change from Baseline Visual evaluation at 3 months after PDT treatment
Secondary Chromameter evaluation Blanching of the PWS lesions was evaluated using a SkinColorCatch" chromameter (Delfin Technologies, Kuopio, Finland). Change from Baseline Chromameter evaluation at 3 months after PDT treatment
See also
  Status Clinical Trial Phase
Terminated NCT04336163 - Skin Imaging to Inform Laser Treatments N/A
Completed NCT00365118 - Treatment of Naevus Flammeus Using Intense Pulsed Light and Pulsed Dye Laser N/A
Completed NCT04106258 - A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain Phase 4
Recruiting NCT05841628 - Tolerability of 532 nm Laser Treatment of Port Wine Stains N/A
Withdrawn NCT00667472 - Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks Phase 1
Completed NCT01924273 - Novel Treatment for Port Wine Stain Birthmarks Phase 1
Terminated NCT02214706 - Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus N/A
Completed NCT00540917 - Measurement Skin Temperature During Pulsed Laser Exposure Phase 2
Suspended NCT04103164 - Pilot Study to Evaluate the Effect of Multiple Passes on Port Wine Stain Treatments With the Cutera Excel V™ Laser. N/A
Completed NCT04999618 - A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology Phase 4
Recruiting NCT05771311 - KTP Laser vs Pulsed Dye Laser for Port-Wine Stains N/A
Completed NCT01775722 - Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment N/A
Completed NCT01774552 - Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment
Not yet recruiting NCT05171894 - A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin + PDT Phase 2
Completed NCT03181984 - Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Phase 4
Completed NCT03125057 - A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain Phase 4
Completed NCT02051101 - Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples N/A